Veru Inc. (VERU): Price and Financial Metrics

Veru Inc. (VERU): $5.61

0.10 (+1.81%)

POWR Rating

Component Grades














  • VERU scores best on the Quality dimension, with a Quality rank ahead of 45.39% of US stocks.
  • The strongest trend for VERU is in Growth, which has been heading down over the past 179 days.
  • VERU ranks lowest in Growth; there it ranks in the 1st percentile.

VERU Stock Summary

  • With a one year PEG ratio of 0.21, VERU INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 2.55% of US stocks.
  • With a year-over-year growth in debt of 145.53%, VERU INC's debt growth rate surpasses 90.99% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, VERU INC is reporting a growth rate of -5,108.95%; that's higher than just 0.31% of US stocks.
  • Stocks that are quantitatively similar to VERU, based on their financial statements, market capitalization, and price volatility, are VLN, BCDA, CLGN, CRDF, and LOGC.
  • VERU's SEC filings can be seen here. And to visit VERU INC's official web site, go to

VERU Valuation Summary

  • In comparison to the median Healthcare stock, VERU's EV/EBIT ratio is 378.95% lower, now standing at -21.2.
  • VERU's price/sales ratio has moved up 15.2 over the prior 243 months.

Below are key valuation metrics over time for VERU.

Stock Date P/S P/B P/E EV/EBIT
VERU 2022-11-01 19.0 8.5 -21.1 -21.2
VERU 2022-10-31 18.7 8.4 -20.9 -20.9
VERU 2022-10-28 18.7 8.4 -20.8 -20.8
VERU 2022-10-27 18.7 8.4 -20.9 -20.9
VERU 2022-10-26 18.5 8.3 -20.6 -20.6
VERU 2022-10-25 17.8 8.0 -19.8 -19.7

VERU Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -130.92%.
  • Its year over year net cashflow from operations growth rate is now at -2559.42%.
  • Its 2 year net income to common stockholders growth rate is now at -176.83%.
Over the past 15 months, VERU's revenue has gone up $2,383,765.

The table below shows VERU's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 52.41218 -27.43297 -47.04789
2022-03-31 60.46558 -26.24523 -27.54518
2021-12-31 60.77767 -24.88806 -16.21333
2021-09-30 61.25953 -15.57102 7.394374
2021-06-30 57.36225 -15.10567 -0.143691
2021-03-31 50.02842 1.067131 -0.476205

VERU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERU has a Quality Grade of C, ranking ahead of 60.52% of graded US stocks.
  • VERU's asset turnover comes in at 0.473 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • INSM, MNKD, and REPH are the stocks whose asset turnover ratios are most correlated with VERU.

The table below shows VERU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.473 0.788 0.038
2021-03-31 0.540 0.756 0.193
2020-12-31 0.760 0.737 0.295
2020-09-30 0.750 0.723 -0.912
2020-06-30 0.691 0.684 -0.376
2020-03-31 0.716 0.696 -0.365

VERU Price Target

For more insight on analysts targets of VERU, see our VERU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.40 Average Broker Recommendation 1.3 (Strong Buy)

VERU Stock Price Chart Interactive Chart >

Price chart for VERU

VERU Price/Volume Stats

Current price $5.61 52-week high $24.55
Prev. close $5.51 52-week low $4.34
Day low $5.36 Volume 1,791,100
Day high $5.84 Avg. volume 10,805,352
50-day MA $10.48 Dividend yield N/A
200-day MA $11.11 Market Cap 449.62M

Veru Inc. (VERU) Company Bio

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.

VERU Latest News Stream

Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream

Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Is It Too Late to Buy Veru Stock?

After Veru (NASDAQ: VERU) got a thumbs-down from a nonbinding advisory committee at the Food and Drug Administration (FDA) on Nov. 9 regarding its drug sabizabulin for the treatment of severe COVID-19, shares of the company fell by more than 60%, and recovery is nowhere in sight. The company is also testing it in a trio of other applications, including for two subtypes of metastatic breast cancer and metastatic treatment-resistant prostate cancer.

Yahoo | November 23, 2022

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 22, 2022

Why Shares of Veru Fell 10.33% on Monday

Veru (NASDAQ: VERU), a biopharmaceutical company that looks for novel cancer therapies, particularly in breast cancer or prostate cancer, saw its shares drop 10.33% on Monday. The company's stock already lost $10 a share two weeks ago when a Food and Drug Administration (FDA) advisory panel voted 8-5 against approving sabizabulin, Veru's COVID-19 oral therapy, via the Emergency Use Authorization route. It's not the last word, but the FDA usually agrees with advisory panels' votes.

Yahoo | November 21, 2022

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

One thing we could say about the analysts on Veru Inc. ( NASDAQ:VERU ) - they aren't optimistic, having just made a...

Yahoo | November 13, 2022

Why Veru Stock Was Losing One-Third of Its Value This Week

The stock of Veru (NASDAQ: VERU) did not have a good week. As of midafternoon Friday, the share price was down by more than 35% week to date, according to data compiled by S&P Global Market Intelligence. Veru and its shareholders had high hopes for sabizabulin, an orally administered COVID treatment.

Yahoo | November 11, 2022

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -54.17%
3-mo -66.35%
6-mo N/A
1-year -27.80%
3-year 164.62%
5-year 375.42%
YTD -4.75%
2021 -31.91%
2020 158.21%
2019 139.29%
2018 22.81%
2017 25.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.715 seconds.